Abstract
In 1907 Alois Alzheimer published the clinical history and pathological findings in a 51-year-old woman with progressive cognitive deterioration and behavior changes. He described the distinct neuro-pathological features that still are recognized as the hallmarks of the disease: senile plaques and neurofibrillary tangles. Until the middle of the twentieth century this disease, now known as Alzheimer’s disease, was considered to be a rare form of presenile dementia, then still clearly separated from senile and arteriosclerotic dementia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References and Further Reading
Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin, 1907; 64: 146–148 (English translation in: Arch Neurol, 1967; 21: 109-110)
Aoki M, Abe K, Oda N, Ikeda M, Tsuda T, Kanai M, Shoji M, Itoyama Y. A presenilin-l mutation in a Japanese family with Alzheimer’s disease and distinctive abnormalities on cranial MRI. Neurology, 1991; 48: 1118–1120
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O’Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology, 1999; 52: 1153–1158
Barra V, Boire JY. Tissue segmentation on MR images of the brain by possibilistic clustering on a 3D wavelet representation. J Magn Reson Imaging, 2000; 11: 267–278
Blacker D, Tanzi RE. The geneties of Alzheimer disease. Arch Neurol, 1998; 55: 294–296
Blessed G, Tomlinson BE, Roth M. The association between qualitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811
Bobinski M, De Leon, Wegel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisnieski HM. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience, 2000; 95: 721–725
Braak H, Braak E. Development of Alzheimer related neuro-fibrillary changes in the neo cortex inversely recapitulate cortical myelination genesis. Acta Neuropathol, 1996a; 92: 197–201
Braak H, Braak E. Evolution of neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl, 1996b; 165 [Suppl]: 3–12
Braak H, Braak E. Neuropathological stages of Alzheimer’s disease. In: de Leon MJ. ed. Atlas of Alzheimer’s disease. New York: Parthenon Publishing, 1999: 57–74
Braak E, Griffing K, Arai K, Bohl J, Bratzke H, Braak H. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci, 1999; 249: 14–22
Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med, 2000; 343: 450–456
Brown WR, Moody DM, Thore CR, Challa VR. Cerebrovascular pathology in Alzheimer’s disease and leukoaraiosis. Ann NY Acad Sci, 2000; 903: 39–45
Brunetti A, Postiglione A, Tedeschi E, Ciarmiello A, Quarantelli M, Covelli EM, Milan G, Larobina M, Soricelli A, Sodano A, Alfano B. Measurement of global brain atrophy in Alzheimer’s disease with unsupervised segmentation of spin-echo MRI studies. J Magn Reson Imaging, 2000; 11:260–266
Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology practice parameters. Neurology, 1997; 49: 925–935
Chui H, Young Lee A. Clinical criteria for various dementia subtypes: Alzheimer disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). In: Qizilbash N, Schneider L, Chui H, Brodaty H, Kaye J, Erkinjuntti T, eds. Evidence based dementia. Oxford: Blackwell Science, 2001, in press
Convit A, De Asis J, De Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease. Neurobiol Aging, 2000; 21: 19–26
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pencak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 828–829
De Leon MJ, Golomb J, George AE, Convit A, Tarshish CY, McRae T, De Santi S, Smith G, Ferris SH, Noz M, Russinek H. The radiologic prediction of Alzheimer’s disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol, 1993; 14:897–906
De Leon MJ, Convit A, George AE, et al. In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer’s disease. Ann N Y Acad Sci, 1996; 17: 1–13
Desmond PM, O’Brien JT, Tress BM, et al. Volumetric and visual assessment of the mesial temporal structures in Alzheimer’s disease. Aust N Z J Med, 1994; 24: 547–553
De Toledo-Morrell L, Goncharova I, Dickerson B, Wilson RS, Bennett DA. From healthy aging to early Alzheimer’s disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci, 2000a; 911: 240–253
De Toledo-Morrell L, Dickerson B, Sullivan MP, Spanovic C, Wilson R, Bennett DA. Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer’s disease. Hippocampus, 2000b; 10: 136–142
Dinsmore ST. Treatment options for Alzheimer’s disease. J Am Osteopath Assoc, 1999; 99 [9 Suppl]: S6–8
Duvernoy HM. The human hippocampus. Berlin Heidelberg New York: Springer, 1998
Erkinjuntti T, Lee DH, Gao F, et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer’s disease. Arch Neurol, 1993; 50: 305–310
Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer’s disease: differentiation with frontal lobe proton MR spectroscopy. Radiology, 1997;203:829–836
Esiri MM, Hyman BT, Beyreuther K, Martus CL. Ageing and dementia. In: Graham DI, Lantos PL, eds. Greenfield’s neuropathology, 5th edn, vol 1. London: Arnold Publishing, 1997: 153–233
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975; 12: 189–198
Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of atrophy in Alzheimer’s disease. Lancet, 1996;348:94–97
Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol, 2000; 57: 339–344
Fox NC, Rossor MN. Diagnosis of early Alzheimer’s disease. Rev Neurol (Paris), 1999; 155: 4 [Suppl]: 33–37
Frisoni GB, Beltramello A, Weiss C, Geroldi C, Bianchetti A, Trabucchi M. Linear measures of atrophy in mild Alzheimer’s disease. AJNR Am J. Neuroradiol 1996; 17: 913–923
Goulding JM, Signorini DF, Chatterjee S, Nicoll JA, Stewart J, Morris R, Lammie G. Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia. J Neurol Neurosurg Psychiatry, 1999;67:654–657
Golomb J, De Leon MJ, Kluger A, George AE, Tarshish C, Ferris SH. Hippocampal atrophy in normal aging. Arch Neurol,1993;50:967–973
Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci, 1997; 20: 54–159
Herminghaus R, Hertel A, Wittsack J, Gorriz C, Moller-Hartmann W, Frohlich L, Dierks T, Lanfermann H, Zanella FE. 99mTC-HMPAO-SPECT and proton MR spectroscopy in the diagnosis of Alzheimer’s disease. Riv Neuroradiol, 1998; 11: 27–30
Hirono N, Yasuda M, Tanimukai S, Kitagaki H, Mori E. Effect of the apolipoprotein E epsilon4-allele on white matter hypointensities in dementia. Stroke, 2000; 31: 1263–1268
Insausti R, Juottonen K, Soininen H, Insausti AM, Partanen K, Vainio P, Laakso MP, Pitkänen A. MR volumetric analysis of the human entorhinal, perirhinal and temporopolar cortices. AJNR Am J Neuroradiol, 1998; 19: 659–671
Jack CR Jr, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology, 2000; 55: 484–489
Kantarci K, Jack CR Jr, Xu YC, Campeau NG, O‘Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H MRS study. Neurology, 2000; 55: 210–217
Kelly CA, Harvey RJ, Cayton H. Drug treatments for Alzheimer’s disease (editorial). BMJ, 1997; 314: 693–694
Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BBT, Albert MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol, 2000; 47: 430–439
Kitagaki H, Mori E, Yamaji S, Ishii K, Hirono N, Kobashi S, Hata Y. Frontotemporal dementia and Alzheimer disease: evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. Radiology, 1998; 208: 431–439
Knopman DS, Morris JC. An update on primary drug therapies for Alzheimer’s disease. Arch Neurol, 1997; 54: 1406–1409
Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H. Hippocampus in Alzheimer’s disease: a 3-year follow-up study. Biol Psychiatry, 2000; 47: 557–561
Massoud F, Devi G, Moroney JT, et al. The role of routine laboratory studies and neuroimaging in the diagnosis of dementia: a clinicopathological study. J Am Geriatr Soc 2000;48: 1204–1210
McKhan G, Drachman D, Folstein M, Katzman R, Price D, Stadian EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:839–944
Meyer JS, Muramatsu K, Mortel KF, Obara K, Shirai T. Prospective CT confirms differences between vascular and Alzheimer’s dementia. Stroke, 1995; 26: 735–742
Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. Cardiovascular and other risk factors for Alzheimer’s disease and vascular dementia. Ann N Y Acad Sci, 2000; 903:411–423
Mizuno K, Wakai M, Takeda, A, Sobue G. Medial temporal atrophy and memory impairment in early stage of Alzheimer’s disease: an MRI volumetric and memory assessment study. J Neurol Sci, 2000; 173: 18–24
Nagata K, Maruya H, Yuja H, Terashi H, Mito Y, Kato H, Sato M, Satoh Y, Watahiki Y, Hirata Y, Yokoyama E, Hatazawa J. Can PET data differentiate Alzheimer’s disease from vascular dementia? Ann N Y Acad Sci, 2000; 903: 252–261
O’Brien JT, Desmond P, Ames D, Schweitzer I, Chiu E, Tress B. Temporal lobe magnetic resonance imaging can differentiate Alzheimer’s disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment. Psychol Med 1997; 27: 1267–1275
Pantel J, Schröder J. Posterior cortical atrophy: ein neues Demenzsyndrom oder Sonderform des morbus Alzheimer? Fortsehr Neurol Psychiatr, 1996; 64: 492–508
Pasquier F, Hamon M, Lebert F, Jacob B, Pruvo JP, Petit H. Medial temporal lobe atrophy in memory dis orders. J Neurol,1997;244: 175–181
Petersen RC, Jack CR Jr, Xu YC, Waring SC, O’Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Boeve BF, Kokmen E. Memory and MRI-based hippocampal volumes in aging and AD. Neurology, 2000; 54: 581–587
Pucci E, Belardinelli N, Regnicolo L, Nolfe G, Signorino M, Salvolini V, Angeleri F. Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer’s disease. Eur Neurol 1998; 39: 16–25
Rombouts SA, Barkhof F, Veltman DJ, Machielson WC, Witter MP, Bierlaagh MA, Lazeron RH, Valk J, Scheltens P. Functional MR imaging in Alzheimer’s disease during memory encoding. AJNR Am J Neuroradiol 2000; 21: 869–875
Saunders DE, Howe FA, Van den Boogaart A, Griffiths JR, Brown MM. Aging of the adult brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J Magn Reson Imaging, 1999; 9: 711–716
Scheltens P, Barkhof F, Valk J, et al. White matter lesions in clinically diagnosed Alzheimer’s disease: evidence for heterogeneity. Brain, 1990; 53: 79–80
Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer’s disease and normal aging: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967–972
Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medical temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 1995; 242: 557–560
Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Jonker C. The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission-computed-tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population. Alzheimer Dis Assoc Disord 1997; 11: 63–70
Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer’s disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65–72
Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease. Ann Neurol, 1999; 45: 466–472
Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M, Hatano K, Sasaki T. Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer’s type and vascular dementia with deep white matter changes. Neuroradiology, 1998; 40: 131–137
Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DMA, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry, 1999; 66: 184–188
Wahlund L-O, Julin P, Lindqvist J, Scheltens P. Visual assessment of medial temporal lobe atrophy in demented and healthy controls: correlation with volumetry. Psychiatry Res 1999;90: 193–199
Wahlund LO, Julin P, Lindqvist J, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry, 2000; 69: 630–635
Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rosor MN. Diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: the role of neurologists in Europe. Eur J Neurol, 2000; 7:133–144
Xu Y, Jack CR Jr, O’Brien PC, Kokmen E, Smith GE, Ivnik RJ, Boeve BF, Tangalos RG, Petersen RC. Usefulness of MRI measured of entorhinal cortex versus hippocampus in AD. Neurology, 2000; 54: 1760–1767
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O’Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies: a comparison with Alzheimer’s disease, vascular dementia and normal ageing. Neurology, 1999a; 52: 1153–1158
Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, Morris CM, O’Brien JT. Apolipoprotein E4 allele, temporal lobe atrophy, and white matter lesions in late life dementias. Arch Neurol, 1999b; 56: 961–965
Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology, 2000;54: 1304–1309
Byrne EJ, Lennox G, Godwin-Austen RB, et al. Dementia associated with cortical Lewy bodies: proposed diagnostic criteria. Dementia, 1990; 2: 283–284
Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry, 1989; 52: 709–714
Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology, 1990;40: 1523–1528
Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, Goldman JE. Diffuse Lewy body disease: neuropathological and biochemical studies of six patients. Acta Neuropathol, 1987; 75: 8–15
Forstl H. The Lewy body variant of Alzheimer’s disease: clinical, pathophysiological and conceptual issues. Eur Arch Psychiatry Clin Neurosci, 1999; 249(3): 64–67
Gibb WRG, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain, 1987; 110: 1131–1153
Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology, 1990; 40: 1–8
Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, Tanimukai S, Hanihara T, Mori E. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology, 1998; 51:357–362
Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol, 2000; 57: 347–351
Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, ed. Handbuch der Neurologie III. Berlin: Springer, 1912: 920–933
Londos E, Passant U, Brun A, Gustafson L. Clinical Lewy body dementia and the impact of vascular components. Int J Geriatr Psychiatry, 2000; 15: 40–49
Lopez OL, Hamilton RL, Becker JT, Wisniewski S, Kaufer DI, DeKosky ST. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies. Neurology, 2000;54: 1780–1787
McKeith I, O’Brien J. Dementia with Lewy bodies. Aust N Z J Psychiatry, 1999; 33: 800–808
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 1996; 47: 1113–1124
McKeith IG, O’Brien J, Ballard C. Diagnosing dementia with Lewy bodies. Lancet, 2000; 354: 1227–1228
Mori E, Shimomura T, Fujimori M, Hirono N, Imamura T, Hashimoto M, Tanimukai S, Kazui H, Hanihara T. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol, 2000; 57: 489–493
Ohara K, Takauchi S, Kokai M, Morimura Y, Nakajima T, Morita Y. Familial dementia with Lewy bodies. Clin Neuropathol, 1999; 18:232–239
Okazaki H, Lipton LS, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadrapesis in flexion. J Neurol Neurosurg Psychiatry, 1961; 20: 237–244
Papka M, Rubio A, Schiffer RB, Cox C. Lewy body disease: can we diagnose it? J Neuropsychiatry Clin Neurosci, 1998;10:405–412
Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type: a clinically and neuro-pathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119–139
Shoji M, Harigaya Y, Veda K, Ishiguro K, Matsubara E, Watanabe M, Ikeda M, Kanai M, Tomidokoro Y, Shizuka M, Amari M, Kosaka K, Nakazato Y, Okamoto K, Hirai S. Accumulation of NACP/alpha-synuclein in Lewy body disease and multiple system atrophy. J Neurol Neurosurg Psychiatry, 2000; 68: 605–608
Baker M, Kwok JBJ, Kucera S, Crook R, Farrer M, Houlden H, Isaacs A, Lincoln S, Onstead L, Hardy I, Wittenberg L, Dodd P, Webb S, Hayward N, Tannenberg T, Andreadis A, Hallupp M, Schofield P, Dark F, Hutton M. Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. Ann Neurol,1997;42:794–798
Basun H, Almkvist O, Axelman K, Brun A, Campbell TA, Collinge I, Forsell C, Froelich S, Wahlund LO, Wetterberg L, Lannfelt L. Clinical characteristics of a chromosome 17-linked rapidly progressive familial frontotemporal dementia. Arch Neurol, 1997; 54: 539–544
Bergmann M, Kuchelmeister K, Schmid KW, Kretschmar HA, Schräder R. Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study. Acta Neuropathol, 1996; 92: 170–179
Brown J. Pick’s disease. Baillieres Clin Neurol, 1992; 1: 535–557
Brown J, Asworth A, Gydesen S. Familial non-specific dementia maps to chromosome 3. Hum Mol Genet 1995; 4:1625–1628
Brun A. Frontal lobe degeneration of non-Alzheimer type revisited. Dementia, 1993; 4: 126–131
Caselli RJ, Windebank AJ, Petersen RC, Komori T, Parisi IE, Okazaki H, Kokmen E, Iverson R, Dinapoli RP. Asymmetric cortical degenerative syndromes. Curr Opin Neurol, 1996;9:276–280
Chang L, Cornford M, Miller BL, Itabashi H, Mena I. Neuronal ultrastructural abnormalities in a patient with frontotemporal dementia and motor neuron disease. Dementia, 1995; 6: 1–8
Cherrier MM, Mendez MF, Perryman KM, Pachana NA, Miller BL, Cummings IL. Frontotemporal dementia versus vascular dementia: differential features on mental status examination. I Am Geriatr Soc, 1997; 45: 579–583
Constantinidis I, Richard J, Tissot R. Piek’s disease: histological and clinical correlations. Eur Neurol, 1974; 11: 208–217
Cooper PN, Jackson M, Lennox G, Lowe J, Mann DM. Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia. Arch Neurol, 1995; 52: 1011–1015
Delacourte A, Robitaille Y, Sergeant N, Buee L, Hof PR, Wattez A, Laroche-Cholette A, Mathieu J, Chagnon P, Gauvreau D. Specific pathological Tau protein variants characterize Piek’s disease. J Neuropathol Exp Neurol, 1996; 55:159–168
Elfgren C, Passant U, Risberg I. Neuropsychological findings in frontal lobe dementia. Dementia, 1993; 4: 214–219
Elfgren C, Ryding E, Passant U. Performance on neuropsychological tests related to single photon emission computerised tomography findings in frontotemporal dementia. Br J Psychiatry, 1996; 169: 416–422
Feany MB, Dickson DW. Neurodegenerative disorders with extensive Tau pathology: a comparative study and review. Ann Neurol, 1996; 40: 139–148
Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol, 1990;55:53–67
Foster NL, Wilhelsen KC, Sima AAF, Jones MZ, D’Amato CJ, Gilman S, and conference participants. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol, 1997; 41: 706–715
Frisoni GB, Beltramello A, Geroldi C, Weiss C, Bianchetti A, Trabucchi M. Brain atrophy in frontotemporal dementia. J Neurol Neurosurg Psychiatry, 1996; 61: 157–165
Froelich S, Basun H, Forsell C, Lilius L, Axelman K, Andreadis A, Lannfelt L. Mapping of a disease locus for familial rapidly progressive frontotemporal dementia to chromo-some 17q21-22. Am J Med Genet, 1997; 74: 380–385
Galton CJ, Gomez-Anson B, Antoun N, Scheltens P, Patterson K, Graves M, Sahakian BJ, Hodges JR. Temporal lobe rating scale: application to Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry, 2001;70: 165–173
Graff-Radford, Stein SD. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol, 1993; 33 200–207
Grossman M, Désposito M, Hughes E, Onishi K, Biassou N, White-Devine T, Robinson KM. Language comprehension proflles in Alzheimer’s disease, multi-infarct dementia, and frontotemporal degeneration. Neurology, 1996;47: 183–189
Gustafson L. Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia, 1993; 4: 143–148
Gustafson L, Abrahamson M, Grubb A, Nilsson K, Fex G. Apolipoprotein-E genotyping in Alzheimer’s disease and frontotemporal dementia. Dement Geriatr Cogn Disord, 1997;8:240–243
Hauw JJ, Duyckaerts C, Seilhean D, Camilleri S, Sazdovitch V, Rancurel G. The neuropathologic diagnostic criteria of frontal lobe dementia revisited: a study of ten consecutive cases. J Neural Transm, 1996; 47: 47–59
Heutink P, Stevens M, Rizzi P, Bakker E, Kros JM, Tibben A, Niermeijer MF, van Duijn CM, Oostra BA, van Swieten JC. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. Ann Neurol, 1997; 41:150–159
Hof PR, Bouras C, Perl DP, Morrison JH. Quantitative neuropathologiC analysis of Pick’s disease cases: cortiCal distribution of Pick bodies and coexistence with Alzheimer’s disease. Acta NeuropathoL, 1994; 87: 115–124
Holister RD, Xia M, McNamara MJ, Hyman BT. Neuronal expression of class II major histocompatibility complex (HLA-DR) in 2 cases of Pick disease. Arch Neurol, 1997; 54:243–248
Hooten WM, Lyketsos CG. Frontotemporal dementia: a clinicopathological review of four postmortem studies. J Neuropsychiatry Clin Neurosci, 1996; 8: 10–19
Jackson M, Lowe J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropathol, 1996; 91:127–134
Jellinger KA. Quantitative neuropathologic analysis of Pick’s disease cases. Acta Neuropathol, 1994; 87: 223–224
Kato S, Oda M, Hayashi H, Kawata A, Shimizu T. Participation of the limbic system and its associated areas in the dementia of amyotrophic lateral sclerosis. J Neurol Sci, 1994; 126:62–69
Kertesz A, Munoz D. Pick’s disease, frontotemporal dementia, and Pick complex. Arch Neurol, 1998; 55:302–304
Kitagaki H, Mori E, Hirono N, Ikejiri Y, Ishii K, Imamura T, Ikeda M, Yamaji S, Yamashita H, Shimomura T, Nakagawa Y. Alteration of white matter MR signal intensity in frontotemporal dementia. AJNR Am J Neuroradiol, 1997; 18:367–378
Kitagaki H, Mori E, Yamaji S, Hirono N, Kobashi S, Hata Y. Frontotemporal dementia and Alzheimer disease: evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. Radiology, 1998;208:431–439
Klüver H, Bucy PC. Preliminary analysis of functions of the temporal lobes in monkeys. Arch Neurol Psychiatry, 1939;42:547–554
Knopman DS, Christensen KJ, Schut LJ, Harbaugh RE, Reeder T, Ngo T, Frey W. The spectrum of imaging and neuropsychological findings in Pick’s disease. Neurology, 1989;39:362–368
Knopman DS, Mastri AR, Frey WH, Sung JH, Rustan T. Dementia lacking distinctive histologic al features: a common non-Alzheimer degenerative dementia. Neurology, 1990;40:251–256
Kobashi S, Kamiura N, Hata Y, Yamato K. 3D-automatic extraction method of the brain regions by fuzzy matching techniques. In: Asian fuzzy systems symposium: soft computing in intelligent systems and information processing. Piscataway, NJ: Institute of Electrical and Electronic Engineers, 1996: 164–175
Leonard BE. Serotonin receptors: where are they going? Int Clin Psychopharmacol, 1994; 9 [Supp 1]: 7–17
Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer disease and frontotemporal dementias: behavioral distinctions. Arch Neurol, 1996; 53: 687–690
Lieberman AP, Trojanowski JQ, Lee VMY, Balin BJ, Ding XS, Greenberg J, Morrison D, Reivich M, Grossman M. Cognitive, neuroimaging, and pathological studies in a patient with Pick’s disease. Ann Neurol, 1998; 43: 259–265
Lund and Manchester groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry, 1994; 57: 416–418
Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AAF, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology, 1994;44: 1878–1884
Mann DMA, South PW, Snowden JS, Neary D. Dementia of the frontal lobe type: neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry, 1993; 56: 605–614
Matsumoto S, Kusaka H, Ito H, Shibata N, Asayama T, Imai T. Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase-positive Lewy bodylike inclusions. Clin Neuropathol, 1996; 15: 41–46
Mendez MF, Cherrier M, Perryman KM, Pachana N, Miller BL, Cummings JL. Frontotemporal dementia versus Alzheimer’s disease: differential cognitive features. Neurology, 1996; 47: 1189–1194
Mendez MF, Selwood A, Mastri AR, Frey WH. Pick’s disease versus Alzheimer’s disease: a comparison of clinical characteristics. Neurology, 1993; 43: 289–292
Miller BL, Cummings JL, Villanueva-Meyer J, Boone K, Mehringer CM, Lesser IM, Mena I. Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology, 1991; 41: 1374–1382
Miller BL, Ikonte C, Ponton M, Levy M, Boone K, Darby A, Berman N, Mena I, Cummings JL. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission tomography and CT correlations. Neurology, 1997; 48: 937–942
Montgomery SA, Fineberg N. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses? Br J Psychiatry, 1989; 155 [Suppl 8]: 63–70
Nagaoka S, Arai H, Iwamoto N, Ohwada J, Ichimiya Y, Nakamura M, Inoue R. A juvenile case of frontotemporal dementia: neurochemical and neuropathological investigations. Prog Neuro-Psychopharmacol Biol Psychiatry, 1995; 19: 1251–1261
Neary D, Snowdon JS. Frontotemporal dementia. In: Pasquier F, Lebert F, Scheltens P, eds. Frontotemporal dementia. Current issues in neurodegenerative disorders, vol 8. Dordrecht: ICG Publications, 1997: 31–48
Neary D, Snowden JS, Northen B, Goulding P. Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry, 1988; 51:353–361
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology, 1998; 51: 1546–1554
Petersen BB, Tabatou M, Chen SG, Monari L, Richardson SL, Lynckes T, Manetto V, Lanska DJ, Markesbery WR, Currier RD, Autilio-Gambetti L, Wilhelmsen KC, Gambetti P. Familial progressive subcortical gliosis. Neurology, 1995; 45: 1062–1067
Pick A. Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prag Med Wochensehr, 1892; 17: 165–167
Pick A. Über primare progressive Demenz bei Erwachsenen. Prag Med Wochensehr, 1904; 29: 417–420
Pick A. Zur Symptomatologie der linksseitigen Schlaffenlappen atrophie. Monatschr Psychiatr (Berlin), 1905; 16: 378–388
Pick A. Über ein weiteres Symptomencomplex im Rahmen der Dementia senilis, bedingt durch umschriebene stärkere Hirnatrophie. Monatschr Psychiatr (Berlin), 1906; 19:97–108
Pookaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L. Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromo-some 17 frontotemporal dementia. Ann Neurol, 1998; 43:815–825
Risberg J. Frontal lobe degeneration of non-Alzheimer type. III. Regional cerebral blood flow. Arch Gerontol Geriatr, 1987;6:225–233
Sima AF, Defendini RF, Keohande D, D’Amato C, Foster NL, Parchi P, Gambetti P, Lynch T, Wilhelmsen KC. The neuropathology of chromosome 17-linked dementia. Ann Neurol,1996;39:734–744
Sparks DC, Markesbery WR. Altered serotinergic and cholinergic synaptic markers in Pick’s disease. Arch Neurol, 1991;48:796–799
Swartz JR, Miller BL, Lesser IM, Booth R, Darby A, Wohl M, Frank Benson D. Behavioral phenomenology in Alzheimer’s disease, frontotemporal dementia and late-life depression: a retrospective analysis. J Geriatr Psychiatry Neurol, 1997a; 10:67–74
Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry, 1997b; 58: 212–216
Talbot PR. Frontal lobe dementia and motor neuron disease. J Neural Transm, 1996; 47: 125–132
Talbot PR, Goulding PJ, Lloyd JL, Snowden JS, Neary D, Testa HJ. Inter-relation between “classic” motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study. J Neurol Neurosurg Psychiatry, 1995; 58: 541–547
Tolnay M, Probst A. Frontal lobe degeneration: novel ubiquitin-immunoreactive neurites within frontotemporal cortex. Neuropathol Appl Neurobiol, 1995; 21: 492–497
Varma AR, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999; 66: 184–188
Vermersch P, Daems-Monpeurt C, Parent M, Pruvo JP, Delacourte A, Petit H. Demence sous-corticale type Neumann. Rev Neurol, 1994; 150: 354–358
Waddington JL, Youssef HA, Farrell MA, Toland J. Initial schizophrenia-like psychosis in Pick’s disease: case study with neuroimaging and neuropathology, and implications for frontotemporal dysfunction in schizophrenia. Schizophrenia Res, 1995; 18: 79–82
Warkentin S, Passant U. Functional imaging of the frontal lobes in organic dementia. Dement Geriatr Cogn Disord, 1997;8: 105–109
Wightman G, Anderson VER, Martin J, Swash M, Anderton BH, Neary D, Mann D, Luthert P, Leigh PN. Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett, 1992; 139: 269–274
Wijker M, Wszolek ZK, Wolters E, Rooimans MA, Pals G, Pfeiffer RF, Lynch T, Rodnitzky RL, Wilhelmsen KC, Arwert F. Localisation of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21. Hum Mol Genet, 1996; 51: 151–154
Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonismamyotrophy complex to 17q21-22. Am J Hum Genet, 1994;55: 1159–1165
Wilhelmsen KC. Disinhibition-dementia-parkinsonismamyotrophy complex (DDPAC) is a non-Alzheimer’s frontotemporal dementia. J Neural Transm, 1997; 49: 269–275
Wong AHC, Van Tol HHM, Schoots O, Shugar G. Familial dementia of the frontal lobe type. Can J Psychiatry, 1995; 41:645–647
Yamaoka LH, Welsh-Bomer KA, Hulette CM, Gaskell C Jr, Murray M, Rimmler JL, Helms BR, Guerra M, Roses ADM, Schmechel DE, Pericak-Vance MA. Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. Am J Hum Genet, 1996; 59: 1306–1312
Abe K, Ukita H, Yanagihara T. Imaging in primary progressive aphasia. Neuroradiology, 1997; 39: 556–559
Aharon-Peretz J, Israel O, Goldsher D, Peretz A. Posterior cortical atrophy variants of Alzheimer’s disease. Dement Geriatr Cogn Disord, 1999; 10: 483–487
Andersen C, Dahl C, Alrnkvist O, Ostberg P, Julin P, Wahlung LO. Bilateral temporal lobe volume reduction paralleis cognitive impairment in progressive aphasia. Arch Neurol, 1997;54: 1294–1299
Ardila A, Roselli M, Arvizu L, Kuljis RO. Alexia and agraphia in posterior cortical atrophy. Neuropsychiatry Neuropsychol Behav Neurol, 1997; 10: 52–59
Balint R. Seelenlähmung des “Schauens”, optische Ataxie, räumliche Störung der Aufmerksamkeit. Monatsehr Psychiatr Neurol, 1909; 25: 51–81
Bauer RM. Agnosia: In: Heilman KM, Valenstein E, eds. Clinical neuropsychology. Oxford: Oxford University Press, 1993
Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol, 1988; 45: 789–793
Benson DF. Posterior cortical atrophy: a new clinical entity or Alzheimer’s disease? Arch Neurol, 1989; 46: 844
Benton A. The neuropsychology of facial recognition. Am Psychol, 1980;35: 176–186
Bruce V, Young A. Understanding facial recognition. Br J Psychol,1986;77:305–327
Caselli RJ, Jack CR. Asymmetric cortical degeneration syndromes. Arch Neurol, 1992; 49: 770–780
Caselli RJ. Asymmetric cortical degeneration syndromes. Curr Opin Neurol, 1996; 9: 276–280
Clarke S, Lindemann A, Maeder P, Borruat FX, Assal G. Face recognition and postero-inferior hemispheric lesions. Neuropsychiologia, 1997; 35: 1555–1563
Cooper PN, Jackson M, Lennox G, Lowe J, Mann DMA. τ, ubiquitin and αß-crystallin immuno-histochemistry define the principal causes of degenerative frontotemporal dementia. Arch Neurol, 1995; 52: 1011–1015
De Gelder B, Rouw R. Paradoxal configuration effects for faces and objects in prosopagnosia. Neuropsychologia, 2000;38: 1271–1279
De Haan EHF, Young AW, Newcombe F. Neuropsychological impairment of face recognition units. Q J Exp Psychol, 1992;44: 141–175
De Renzi E, Faglioni P, Spinnler H. The performance of patients with unilateral brain damage on facial recognition tasks. Cortex, 1968; 26: 16–33
Delay J, Neveu P, Desclaux P. La forme pariéto-occipitale de la maladie de Pick. Etude de l’agnosie visuelle. Rev Neurol (Paris), 1944; 76: 264–265
Duchenne BC. Developmental prosopagnosia with normal configural processing. Neuroreport, 2000; 11: 79–83
Edwards-Lee T, Miller BL, Benson DF, Cummings JL, Russell GL, Boone K, Mena I. The temporal variant of frontotemporal dementia. Brain, 1997; 120: 1027–1040
Graff-Radford NR, Damassio AR, Hyman BT, Hart MN, Tranel D, Damasio AR, Hyman BT, Hart MN, Tranel D, Damasio H, Van Hoesen GW, Rezai K. Progressive aphasia in a patient with Pick’s disease. Neurology, 1990; 40: 620–626
Kertesz A, Minoz D. Primary progressive aphasia. Clin Neurosci, 1997; 4: 95–102
Kleist K. Gehirnpathologie. In: Handbuch der ärztlichen Erfahrungen im Weltkrieg 1914/1918, vol IV. Leipzig: Barth,1922-1934
Lang AE, Maragonore D, Marsden CD, Tanner C. Movement Disorder Society symposium on cortico-basal ganglionic degeneration (CBGD) and its relationship to other asymmetrical cortical degeneration syndromes. Mov Disord 1996; 11: 346–357
Mattson AJ, Levin HS, Grafman J. A case of prosopagnosia following moderate closed head injury with left hemisphere focal lesion. Cortex, 2000; 36: 125–137
Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol, 1982; 11: 592–598
Miller BL, Chang L, Mena J, Boone K, Lesser IM. Progressive right frontotemporal degeneration: clinical, neuropsychological and SPECT characteristics. Dementia, 1993; 4: 204–213
Nakamura K, Kawashima R, Sato N, Nakamura A, Sugiura M, Kato T, Ito K, Fukuda H, Schormann T, Zilles K. Functional delineation of the human occipito-temporal areas related to faces and scene processing: a PET study. Brain, 2000;123: 1903–1912
Neary D, Snowden JS, Mann DMA. Familial progressive aphasia: its relationship to other forms of lobar atrophy. J Neurol Neurosurg Psychiatry, 1993; 56: 1122–1125
Pantel J, Schröder J. “Posterior cortical atrophy”: ein neues Demenzsyndrom oder Sonderform des Morbus Alzheimer? Fortsehr Neurol Psychiatr, 1996; 64: 492–508
Rosler A, Lanquillon S, Dippel O, Braune HJ. Impairment of facial recognition in patients with right cerebral infarcts quantified by computer aided “morphing”. J Neurol Neurosurg Psychiatry, 1997; 62: 261–264
Ross SJ, Graham N, Stuart-Green L, Prins M, Xuereb J, Patterson K, Hodges JR. Progressive biparietal atrophy: an atypical presentation of Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 1996; 61: 388–395
Snowden JS, Gouldring PJ, Neary D: Semantic dementia: a form of circumscribed cerebral atrophy. Behav Neurol, 1989;2: 167–182
Snowden JS, Neary D, Mann DMA, Goulding PJ, Testa HJ. Progressive language disorder due to lobar atrophy. Ann Neurol, 1992a; 31: 174–183
Snowden JS, Neary D, Mann DMA, Goulding PJ, Testa HJ. Progressive language disorder due to lob ar atrophy. Ann Neurol 1992b;31: 174–183
Scheltens Ph, Hazenberg GJ, Lindeboom J, Valk J, Wolters EC. A case of progressive aphasia without dementia: “temporal” Pick’s disease? J Neurol Neurosurg Psychiatry, 1990;53:79–80
Scheltens P, Ravid R, Kamphorst W. Pathologic findings in a case of primary progressive aphasia. Neurology, 1994; 44:279–282
Takamura M. Prosopagnosia: a look at the laterality and specificity issues using evidence from neuropsychology and neurophysiology. The Harvard Brain, 1996; [spring]: 9–13
Tyrrell PJ, Warrington EK, Frackowiak RSJ, Rossor MN. Progessive degeneration of the right temporal lobe studied with positron emission tomography. J Neurol Neurosurg Psychiatry, 1990; 53: 1046–1050
Tyrrell PJ, Warrington EK, Frackowiak RSJ, Rossor MN. Heterogeneity in progressive aphasia due to focal cortical atrophy. Brain, 1990; 113: 1321–1336
Tyrrell PJ, Warrington ER, Frackowiak RSJ, Rossor MN. Progressive degeneration of the right temporal lobe: studies with positron emission tomography. J Neurol Neurosurg Psychiatry, 1990; 53: 1046–1050
Adachi M, Hosoya T, Halm T, Yamaguchi K, Kawanami T. Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted imaging. AJNR Am J Neuroradiol, 1999; 20: 1500–1506
Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive nuclear palsy. J Neurol Neurosurg Psyschiatry, 1974; 37: 121–130
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997; 12:33–38
Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm, 1998;105: 1213–1228
Bajaj NP, Shaw C, Warner T, RayChaudhuri K. The genetics of Parkinson’s disease and parkinsonian syndromes. J Neurol,1998;245:625–633
Ball B. De I’insanité dans le paralysie agitans. Encephale, 1882;2:22–32
Barbeau A. The pathogenesis of Parkinson’s disease: a new hypothesis. Can Med Assoc J, 1962; 87: 802–807
Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J. MRI evaluation of brain iron in earlier-and later-onset Parkinson’s disease and normal subjects. Magn Reson Imaging, 1999; 17: 213–222
Bejanni BP, Dormont D, Pidoux B, Yelnik J, Damier P, Arnulf I, Bonnet AM, Marsault C, Agid Y, Philippon J, Cornu P. Bilateral subthalamic stimulation for Parkinson’s disease by using three dimensional stereotactic magnetic resonance imaging and electrophysiologic guidance. J Neurosurg, 2000; 92: 615–625
Bordet R, Broly F, Destee A. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson’s disease. Adv Neurol, 1996; 65: 97–100
Brooks DJ. Functional imaging of Parkinson’s disease: is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl, 1999; 56: 139–153
Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustarii B, Bjorklund A, Brooks DJ, Marsden CD, Oertel WH, Quinn NP, Rehncrona S, Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue trated with lazaroids in Parkinson’s disease. Brain 2000; 123: 1380–1390
Cedarbaum JM, Gandy SE, McDowell E “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson’s disease. Neurology, 1991; 41: 622–629
Chan P, Tanner CM, Hang X, Langston JW. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson’s disease. Neurology,1998; 50: 513–514
Charcot JM. Lectrues on the diseases of the nervous system. London: The New Sydenham Society, 1877
Colcher A, Simuni T. Clinical manifestations of Parkinson’s disease. Med Clin North Am, 1999; 83: 327–347
Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multicenter study of Parkinson mortality with early versus late treatment with L-dopa. Ann Neurol, 1987;22:8–12
Diederich NJ, Hilder C, Goetz CG, Keipes M, Hentges F, Metz H. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson’s disease. Ann Neurol, 1996;40:233–234
DiMauro S. Mitochondrial involvement in Parkinson’s disease. Neurology, 1993;43:2170–2172
Fahn S. Parkinson disease, the effect of levodopa, and the L-DOPA trial. earlier vs later L-DOPA. Arch Neurol, 1999; 56:529–535
Freeman TB, Olanow CW, Hauser RA. Bilateral fetal nigral transplantation to the postcommissural putamen in Parkinson’s disease. Ann Neurol, 1995; 38: 379–388
Gelman N, Gorell JM, Barker PB, Savage RM, Spickler EM, Windham JP, Knight RA. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology, 1999; 210: 759–767
Gibb WRG, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain, 1985; 110: 1131–1153
Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol, 1990; 27: 276–282
Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology, 1995; 45: 1138–1143
Grasbon-Frodl EM, Kosel S, Riess O, Muller U. Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson’s disease patients. Biochem Biophys Res Commun, 1999; 255: 749–752
Greenmyre JL, O’Brien CF. NMDA antagonists in the treatment of Parkinson’s disease. Arch Neurol, 1991; 48: 977–981.
Hagell P, Crabb L, Pogarell O, Schrag A, Widner H, Brooks DJ, Oertel WH, Quinn NP, Lundvall O. Health-related quality of life following bilateral instrastriatal transplantation in Parkinson’s disease. Mov Disord 2000; 15: 224–229
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of MPTP by monoamine oxidase inhibitors. Nature, 1984; 311: 467–469
Hutchinson M, Raff U. Parkinson’s disease: a novel method for determining structural changes in the substantia nigra. J Neurol Neurosurg Psychiatry, 1999; 67: 815–818
Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson’s disease as revealed by MR imaging. AJNR Am J Neuroradiol, 2000; 21: 697–701
Jankovic J, Cardoso F, Grossman RG, Hamilton J. Outcome after stereotaxic thalamotomy for parkinsonism, essential, and other types of tremor. Neurosurgery, 1995; 37:680–686
Johansson F, Malm J, Nordh E, Hariz M. Usefulness of pallidotomy in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry, 1997; 62: 125–132
Koller W, Phawa R, Busenbark K, et al. High-frequency uni-lateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol, 1997; 42: 292–299
Koller WC, Tolosa E. Current and emerging drug therapies in the management of Parkinson’s disease. Neurology, 1998;50: S1
Kraft E, Winkelmann J, Trenkwalder C, Auer DP. Visual hallucinations, white matter lesions and disease severity in Parkinson’s disease. Acta Neurol Scand, 1999; 99: 362–367
Levivier M, Dethy SSS, Rodesch F, Peschanski M, Vandesteene A, David P, Wikleer D, Goldman S, Claes T, Biver F, Liesnard C, Goldman M, Hildebrand J, Brotchi J. Intracerebral transplantation of fetal mesencephalon for patients with advanced Parkinson’s disease: methodology and 6-month to 1-year follow-up in three patients. Stereotact Funct Neurosurg 1997; 69: 99–111
Lewy FH. Die Lehre vom Tonus und Bewegung. Berlin, Springer, 1923
Louis ED, Goldman JE, Powers JM, Fahn S. Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord, 1995; 10(Suppl 2):188–194
Marek K, Seibyl JP, Zoghbi SS. J-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology, 1996; 46: 231–237.
Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet, 1998; 352: 1344–1346
Messa C, Volonte MA, Fazio F, et al. Differential distributionof striatal [123I]beta-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with singlephoton emission tomography. Eur J Nucl Med, 1998; 25:1270–1276
Nutt JG, Carter JH, Van Houten L, Woodward WR. Shortand long-duration responses to levodopa during the first year oflevodopa therapy. Ann Neurol, 1997; 42: 349–355.
Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation for the treatment of Parkinson’s disease. Trends Neurosci, 1996; 19: 102–108
Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol, 1989; 26: 719–723
Parkinson J. An essay on the shaking palsy. Med Classics, 1817; 10: 964–997
Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a five year follow-up. Neurology, 1987; 37: 826–828
Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson’s disease. Neurology, 1999; 52: 1417–1421
Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, Quinn NP. Differentiation of atypical parkinsonian syndromes with routine MR. Neurology, 2000; 54: 697–7021
Smargiassi A, Mutti A, DeRosa A, DePalma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy. Neurotoxicology, 1998; 19: 709–712
Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson’s disease: a historical perspective. Mov Disord, 1998; 13: 582–588
Sutton JB, Couldwell W, Lew MF. Ventroposterior medial pallidotomy in patients with advanced Parkinson’s disease. Neurosurgery, 1995;36: 1112–1117
Tanner CM, Ottman R, Goldman SM, et al. Parkinson’s disease in twins: an etiologic study. JAMA, 1999; 281: 341–346
Tsuneoka Y, Matsuo Y, Ichikawa Y, Watanabe Y. Genetic analysis of the CYP2D6 gene in patients with Parkinson’s disease. Metabolism, 1998; 47: 94–96
Vingerhoets G, van der Linden C, Lannoo E. Cognitive outcome after unilateral pallidal stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 1999; 66: 297–304
Vitek JL, Hashimoto T, Kaneoke Y. Improvement of parkinsonian motor signs during electrical stimulation of the pallidum. Mov Disord, 1994; 9 (Suppl 1): 102
Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson’s disease and patients with multiple system atrophy: relation to iron content. Radiology, 1999; 211: 489–495
Wang WW, Khajavi M, Patel BJ, Beach J, Jankovic J. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson’s disease in nonGreek and/or Italian populations. Arch Neurol, 1998; 55: 1521–1523
Wooten GF, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker WD Jr. Maternal inheritance in Parkinson’s disease. Ann Neurol, 1997; 41: 265–268
Youdin MBH, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson’s disease. Mov Disord, 1993; 8 (Suppl 1): 1–12
Zareparsi S, Kay J, Camicioli R, et al. Analysis of the alpha-synuclein G209A mutation in familial Parkinson’s disease. Lancet, 1998;351:37–38
Blin J, Vidailhet MJ, Pillon B, Dubois F, Feve JR, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord, 1992;7:348–354
Brunt ERP, Van Weerden TW, Pruim J, Lakke JWPF. Unique myoclonic pattern in corticobasal degeneration. Mov Disord, 1995; 10: 132–142
Eidelberg D. Differential diagnosis of Parkinson’s disease with [18F]fluorodesoxyglucose and PET. Mov Disord, 1996; 11: 349
Eidelberg D, Moeller JR, Sidtis JJ, Dhawar V, Strother SC, Pahn S, Rottenberg DA. Cortico-dentato-nigral degeneration: metabolic asymmetries studied with 18F-PDG and PET. Neurology, 1989; 39 (Suppl 1): 164–169
Doi T, Iwasa K, Makifuchi T, Takamori M. White matter hyperintensities on MRI in a patient with corticobasal degeneration. Acta Neurol Scand, 1999; 99: 199–201
Gallucci M, Bonamini M, Catalucci A, Leuzzi V, Micheli C, Caulo M, Scarnati E. MRI helps in the early diagnosis of corticobasal degeneration. Riv Neuroradiol, 1998: 11 (Suppl 2): 13–14
Katagaki H, Hirono N, Ishii K, Mori E. Corticobasal degeneration: evaluation of cortical atrophy by means of hemispheric surface display generated with MR images. Radiology, 2000; 216: 31–38
Lang AE, Maragonore D, Marsden CD, Tanner C. Movement disorder society symposium on corticobasal ganglionic degeneration and its relationship to other asymmetrical cortical syndromes. Mov Disord, 1996; 11: 346–357
Lippa CP, Smith TW, Fonteau N. Corticonigral degeneration with neuronal achromasia: a clinicopathologic study of two cases. J Neurol Sci, 1990; 98: 301–310
Pollanen MS, Ksiezak-Reding H. The emerging molecular pathology of corticobasal ganglionic degeneration. Mov Disord,1996;11:350
Rebeiz JJ, Kolodny EH, Richardson EP. Cortico-dentato-nigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967;92:23–26
Revesz T, Daniel SE. Corticobasal degeneration. In: Markesbery WR, ed. Neuropathology of dementing disorders. London: Edward Arnold, 1998: 257–267
Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: a clinical study of 36 cases. Brain, 1994; 117: 1183–1196
Tokomaru AM, O’uchi T, Kuru Y, Maki T, Murayama S, Horochi Y. Corticobasal degeneration: MR with histopathological comparison. AJNR Am J Neuroradiol, 1996; 17: 1849–1852
Aldrich MS, Foster NL, White RF, Bluemlein L, Prokopowicz G. Sleep abnormalities in progressive supranuclear palsy. Ann Neurol, 1989; 25: 577–581
Anouti A, Schmidt K, Lyons KE, et al. Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Neurology, 1996; 46: 1156–1157
Barclay CL, Bergeron C, Lang AE. Arm levitation in progressive supranuclear palsy. Neurology, 1999; 52: 879–882
Bigio EH, Brown DF, White CL. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol, 1999; 58: 359–364
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology, 1997;49: 1284–1288
Brooks DJ. Positron emission tomographic studies of the subcortical degenerations and dystonia. Semin Neurol, 1989;9:351–359
Caparros-Lefevbre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet, 1999; 354:281–286
Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Ann Neurol, 1999; 46: 325–332
Conrad E, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supra-nuclear palsy. Ann Neurol, 1997; 41: 277–281
Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol, 2000; 47: 718–728
Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord, 1997; 12: 767–771
Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. Risk factors for progressive supranuclear palsy. Neurology, 1988; 38: 1546–1552
Golbe LI, Davis PH, Lepore FE. Eyelid movement abnormalities in progressive supranuclear palsy. Mov Disord, 1989;4:297–302
Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology, 1988; 38: 1031–1034
Golbe LI, Rubin RS, Cody RP, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology, 1996;47: 148–154
Grafman J, Litvan I, Gomez C, Chase TN. Frontal lobe function in progressive supranuclear palsy. Arch Neurol, 1990;47:553–558
Guillain G, Mollaret P. Deux cas de myoclonies synchrones et rhythmées vélo-pharngo-laryngo-oculo-diaphragmatiques. Rev Neurol, 1931; 2: 245–266
Habert MO, Smampinato U, Mas JL, et al. A comparative technetium-99m hexamethylpropylene amine oxime SPET [sic] study in different types of dementia. Eur J Nucl Med, 1991; 18:3–11
Ishizawa K, Lin WL, Tiseo P, Honer WG, Davies P, Dickson DW. A qualitative and quantitative study of grumose degeneration in progressive supranuclear palsy. J Neuropathol Exp Neurol, 2000; 59: 513–524
Jackson JA, Jankovic J, Ford J. Progress supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol, 1983; 13: 273–278
Jankovic J. Progressive supranuclear palsy: clinical and pharmacologic update. Neurol Clin, 1984; 2: 473–486
Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl 1980; 16: 111–128
Litvan I, Agid Y, eds. Progressive supranuclear palsy. New York: Oxford University Press, 1992
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH. Clinical research criteria for the diagnosis of progressive supra-nuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology, 1996;47: 1–9
Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, Chase TN. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol, 1989; 26: 404–407
Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology, 1986; 36: 1005–1008
Pfaffenbach DD, Layton DD, Kearns TP. Ocular manifestations in progressive supranuclear palsy. Am J Ophthalmol, 1972; 74: 1179–1184
Rojo A, Pernaute RS, Fontan A, et al. Clinical genetics of familial progressive supranuclear palsy. Brain, 1999; 122: 1233–1245
Savoiardo M, Strada L, Girotti F, D’Incerti L, Ibena M, Soliveri P, Balzarini L. MR imaging in progressive supranuclear palsy and Shy-Drager syndrome. J Comput Assist Tomogr, 1989;13:555–560
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet, 1999; 354: 1771–1775
Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, Quinn NP. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology, 2000; 54: 697–702
Soliveri P, Monza D, Paridi D, Radice D, Grisoli M, Testa D, Savoiardo M, Girotti F. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology, 1999; 53:502–507
Sonies BC. Swallowing and speech disturbances. In: Litvan I, Agid Y, eds. Progressive supranuclear palsy: clinical and research approaches. New York: Oxford University Press, 1992
Stanford PM, Halliday GM, Brooks WS, Kwok JB, Storey CE, Creasey H, Morris JG, Fyulham MJ, Schofield PR. Progressive supranuclear palsy pathology caused by a novel mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain, 2000;123:880–893
Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol, 1964; 10: 333–359
Tolosa E, Duvoisin R, Cruz-Sanchez FF, eds. Progressive supranuclear palsy: diagnosis, pathology and therapy. J Neural Transm Suppl, 1994; 42: 15–31
Yagishita A, Oda M. Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology, 1996; 38: 60–66
Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl, 1994; 42: 189–201
Abe H, Yagishita S, Amano N, Iwabuchi K, Hasegawa K, Kowa K. Argyrophilic glial intracytoplasmic inclusions in multiple system atrophy: immunocytochemical and ultrastructural study. Acta Neuropathol, 1992; 84: 273–277
Adams RD, van Bogaert L, van der Eecken H. Striato-nigral degeneration. J Neuropathol Exp Neurol, 1964; 23: 584–608
Antonini A, Schwartz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord, 1997; 12:33–38
Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. I. Neuronal cytoplasmic inclusions. Acta Neuropathol, 1992; 3: 453–460
Barbiroli B, Martinelli P, Patuelli A, Lodi R, Iotti S, Cortelli P, Montagna P. Phosphorus magnetic resonance spectro-scopy in multiple system atrophy and Parkinson’s disease. Mov Disord, 1999; 14: 430–435
Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol, 1994: 151: 1336–1341
Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology, 1997; 48: 384–393
Brooks DI, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AI, Marsden CD, Bannister R, Frackowiak RS. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol, 1992;31: 184–192
Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, Muller C, Podreka I. Measurement of the doraminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Transm Suppl, 1997;50:9–24
Déejerine I, Thomas A. L’atrophie olivopontocerebelleuse. Nouv Iconogr Salpet, 1900; 13: 330–370
Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol, 1999; 9:721–731
Frumkin H. Multiple system atrophy following chronic carbon disulfide exposure. Environ Health Perspect, 1998; 106: 611–614
Gai WP, Power IH, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new alpha-synuclein disease? Lancet, 1998;352:547–548
Gilman S, Low Pa Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci, 1999a; 163: 94–98
Gilman S, Koeppe R, Junck L, Little R, Kluin KJ, Heumann M, Martorello S, Johanns J. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol, 1999b; 45:769–777
Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry, 1969; 32: 28–34
Harding AE. Commentary: olivopontocerebellar atrophy is not a useful concept. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworth, 1987: 269–271
Horimoto Y, Aiba I, Yasuda T, Ohkawa Y, Katayama T, Yokokawa Y, Goto A, Ito Y. Cerebral atrophy in multiple system atrophy by MRI. J Neurosci, 2000; 173: 109–112
Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry, 1992; 55: 1009–1013
Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med, 1993; 93: 38–48
Kato S, Nakamura H, Hirano A, Ito H, Llena JF, Yen SH. Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol, 1991; 82:488–493
Kim GM, Kim SE, Lee WY. Preclinical impairment of the striatal dopamine transporter system in sporadic olivo-pontocerebellar atrophy: studied with [123I]ßCIT and SPECT. Eur Neurol, 2000; 43: 23–29
Kirby R, Fowler C, Gosling F, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry, 1986; 9:554–562
Konagaya M, Konagaya Y, Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry, 1994;57:1528–1531
Konagaya M, Sakai M, Matsuoka Y, Goto Y, Yoshida M, Hashizume Y. Pathological correlate of the slitlike changes on MRI at the putaminal margin in multiple system atrophy. J Neurol, 1999; 246: 142–143
Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol, 1999; 56: 225–228
Munschauer FE, Loh L, Bannister R, Newsom-Davis J. Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure. Neurology 1990;40:677–679
Murayama S, Arima K, Nakazato Y, Satoh J, Oda M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. II. Oligodendroglial cytoplasmic inclusions. Acta Neuropathol, 1992; 84: 32–38
Papp M, Kahn J, Lantos P. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci, 1989; 94: 79–100
Papp ML, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain, 1994; 117: 235–243
Parati EA, Fetoni V, Geminiani GC, et al. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol, 1993;16: 139–144
Plazzi G, Corsini R, Provini F, et al. REM sleep behavior disorders in multiple system atrophy. Neurology, 1997; 48:1094–1097
Polinsky RJ. Shy-Drager syndrome. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders. Baltimore: Williams and Wilkins, 1993: 191–204
Quinn NP, Luthert P, Honavar M, Marsden CD. Pure akinesia due to Lewy body Parkinson’s disease: a case with pathology. Mov Disord, 1989; 4: 85–88
Quinn NP, Wenning GK. Multiple system atrophy. Adv Neurol, 1996; 69: 413–419
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross sectional study. Lancet, 1999; 354: 1771–1775
Schrag A, Quinn N. Disorders of the basal ganglia and their modern management. J. R Coll Physicians Lond 1999; 33:323–327
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet, 1999; 354: 1771–1775
Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K, Dichgans J, Klockgether T. Magnetic resonance imaging based volumetry differentiates Parkinson’s syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol, 1999; 45: 65–74
Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathological study. Arch Neurol, 1960; 2: 511–512
Siemers E. Multiple system atrophy. Med Clin North Am, 1999;83:381–392
Singer C. Urinary dysfunction in Parkinson’s disease. Clin Neurosci, 1998; 5: 78–86
Terakawa H, Abe K, Watanabe Y, Nakamura M, Fujita N, Hirakubi N, Yanagihara T. Proton magnetic resonance spectroscopy in patients with sporadic cerebellar degeneration. J Neuroimaging, 1999; 9: 72–77
van der Eecken H, Adams RD, van Bogaert L. Striopallidalnigral degeneration: a hitherto undescribed lesion in paralysis agitans. J Neuropathol Exp Neurol, 1960; 19: 159–161
Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson’s disease, and patients with multiple system atrophy: relation to iron content. Radiology, 1999; 211; 489–495
Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain, 1994; 117: 835–845
Wenning GK, Kraft E, Beck R, et al. Cerebellar presentation of multiple system atrophy. Mov Disord, 1997; 12: 115–117
Ikeuchi T, Koide R, Onodera O, Tanaka H, Oyake M, Takano H, Tsuji S. Dentatorubral-pallidoluysian atrophy (DRPLA): molecular basis for wide clinical features of DRPLA. Clin Neurosci, 1995; 3: 23–27
Koide R, Onodera O, Ikeudu T, Kondo R, Tanada H, Tokiguchi S, Tonmoda A, Miiko T, Isa F, Beppu H, Shimuzi N, Watanada Y, Horikawa Y, Dhenokata T, Hirota K, Ishikawa A, Tsuji S. Atrophy of the cerebellum and brain stem in dentatorubral-pallidoluysian atrophy: influence of GAG repeat size on MR findings. Neurology, 1997; 49:1605–1612
Melberg A, Dahl N, Hetta J, Valind S, Nennesmo I, Lundberg PO, Raininko R. Neuroimaging study in autosomal dominant cerebellar ataxia, deafness and narcolepsy. Neurology, 1999; 53: 2190–2192
Miyazaki M, Hashimoto T, Yoneda Y, Tayama M, Harada M, Miyoshi H, Kawano N, Murayama N, Kondo I, Kuroda Y. Proton magnetic resonance spectroscopy on childhoodonset dentatorubral-pallidoluysian atrophy (DRPLA) Brain Dev, 1996; 18: 142–145
Munoz E, Mila M, Sanchez A, Latorre P, Ariza A, Codina M, Ballesta F, Tolosa E. Dentatorubropallidoluysian atrophy in a Spanish family: a clinical radiological, pathological and genetic study. J Neurol Neurosurg Psychiatry, 1999; 67: 811–814
Smith JK, Gonda VE, Malamud N. Unusual form of cerebellar ataxia: combined dentatorubral and pallidoluysian degeneration. Neurology, 1958; 13: 266–269.
Smith JK. Dentatorubropallidoluysian atrophy. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. Amsterdam: North-Holland, 1975: 519–534
Tomiyasu H, Yoshii F, Ohnuki I, Ikeda JE, Shinohara Y. The brainstem and thalamic lesions in dentatorubral-pallidoluysian atrophy: an MRI study. Neurology, 1998; 50:1887–1890
Uyama E, Kondo I, Uchino M, Fukushima T, Murayama N, Kwano A, Inokuchi N, Ohthari Y, Ando M. Dentatorubral-pallidoluysian atrophy (DRPLA): clinical, genetic and neuroradiologic studies in a family. J Neurol Sci, 1995;130: 146–153
Warner TT, Lennox GC, Janota I, Harding E. Autosomaldominant dentatorubropallidoluysian atrophy in the United Kingdom. Mov Disord, 1994; 3: 289–296
Warner TT, Williams LD, Walker RWH, Flinter F, Robb SA, Bundey SE, Honavar M, Harding AE. A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four European families. Ann Neurol, 1995; 37:452–459
Yoshii F, Tomiyashu H, Shinohara Y. Fluid attenuation inversion recovery (FLAIR) images of dentatorubral-pallidoluysian atrophy: a case report. J Neurol Neurosurg Psychiatry, 1998; 65: 396–399
Duncan MRW, Steele JC, Kopin IJ, Markey SP. 2-Amino-3-methylaminopropanoic acid (BMAA) in Cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam. Neurology, 1990; 40:767–772
Durlach J, Bac P, Durlach V, Bara M, Guiet-Bara A. Are agerelated neurodegenerative diseases linked with various types of magnesium depletion? Magn Reson, 1997; 10:339–353
Hirano A, Kurland LT, Krooth RS, Lesell LS. Parkinson-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain, 1961a; 84: 642–661
Hirano A. Malamud N, Kurland LT. Parkinson-dementia complex, an endemic disease on the island of Guam. II. Pathological features. Brain, 1961b; 84: 662–679
Kato S, Hirano A, Liena JF, Yen SH. Ultrastructural identification of neurofibrillary tangles in the spinal cords in Guamanian ALS and parkinsonism-dementia complex on Guam. Acta Neuropathol, 1992; 53: 277–282
Kurlans LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana islands, including clinical and pathologic observations. Neurology, 1954; 4: 355–378
Lillienfeld DE, Peil DP, Olanon CW. Guam neurodegeneration. In: Carnie DB, ed. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994: 895–898
McGeer PL, Schwab C, McGeer EG, Haddock RL, Steele JC. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. Neurology, 1997; 49: 400–409
Perl DP, Good PF. Aluminum, Alzheimer’s disease, and the olfactory system. Ann N YAcad Sci, 1991; 640: 8–12
Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC. Guam amyotrophic lateral sclerosisparkinsonism-dementia linked to a plant excitant neurotoxin. Science, 1987; 237: 517–522
Yasui M, Ota K, Garruto RM. Concentration of zinc and iron in the brains of Guamanian patients with ALS and parkinsonism-dementia. Neurotoxicology, 1993; 14: 445–450
Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry, 1974; 37: 121–130
Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA. Longitudinal change in basal ganglia volume in patients with Huntington’s disease. Neurology, 1997; 48: 394–399
Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain, 1997; 120:2207–2217
Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors, 1999;9:261–266
Besret L, Kendall AL, Dunnett SB. Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington’s disease. J Anat, 2000; 196: 597–607
Dose M, Lange HW. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry, 2000; 33: 19–27
Fink JJJS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, Penn R, Starr P, Van Horne C, Kott HS, Dempsey PK, Fischman AJ, Raineri R, Manhart C, Dinsmore J, Isacson O. Porcine xenografts in Parkinson’s disease and Huntington’s disease patients: preliminary results. Cell Transplant, 2000; 9: 273–278
Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relation between trinucleotide repeats and neuropathological changes in Huntington’s disease. Ann Neurol, 1996; 39: 132–136
Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetyl aspartate/choline ratio in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry, 1997; 62: 27–30
Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in presymptomatic, gene-tested persons at-risk for Huntington’s disease. Brain 1999; 122: 1667–1678
Jenkins BG, Koroshetz WI, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized proton spectroscopy. Neurology, 1993; 43: 2689–2695
Kowall NW, Ferrante RJ. Huntington’s disease. In: Markesbery WR, ed. Neuropathology of dementing disorders. London: Edward Arnold, 1998: 219–256
Kremer B, Clark CM, Almquist EW, Raymond LA, Graf P, Jacova C, Hardy MA, Snow B, Martin W, Hayden MR. Influence of lamotrigine on progression of early Huntington’s disease: a randomized clinical trial. Neurology, 1999;53: 1000–1011
Mapother E. Mental symptoms in association with chorei-form disorders. J Mental Sci 1911; 57: 641–661
Muller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabis in movement disorders. Forsch Komplementarmed, 1999;6:23–27
Nance MA. Huntington’s disease: another chapter rewritten (invited editorial). Am J Hum Genet, 1996; 59: 1–6
Nance MA. Genetic testing of children at risk for Huntington’s disease. Neurology, 1997; 49: 1048–1053
Rosas HD, Korohetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME. Mov Disord, 1999; 14: 326–330
Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington’s disease. Neurology, 1999; 53:806–812
Ardila A, Roselli M, Arvizu L, Kuljis RO. Alexia and agraphia in posterior cortical atrophy. Neuropsychiatry Neuropsychol Behav Neurol, 1997; 10: 52–59
Benson DF. Posterior cortical atrophy: a new clinical entity, or Alzheimer’s disease? In reply. Arch Neurol, 1989; 46:843–844
Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol, 1988; 45: 789–793
Bergmann M, Gullotta F, Weitbrecht WU. Progressive subkortikale Gliose. Fortschr Neurol Psychiatr, 1991; 59:328–334
Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr, 1987; 6: 193–208
Constantinidis J, Richard J, Tissot R. Pick’s disease: histological and clinical correlations. Eur Neurol, 1974; 11: 208–217
Englund E, Brun A. Frontal lobe degeneration of non-Alzheimer type. IV. White matter changes. Arch Gerontol Geriatr, 1987; 6: 235–243
Goedert M, Spillantini MG, Crowther RA, Chen SG, Parchi P, Tabaton M, Lanska DJ, Markesbery WR, Wilhelmsen KC, Dickson DW, Petersen RB, Gambetti P. Tau gene mutation in familial progressive subcortical gliosis. Nature Med, 1999; 5: 1–4
Gustafson L. Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr, 1987; 6: 209–223
Khoubesserian P, Davous P, Bianco C, Puyirat J. Demence familiale de type Neumann (gliose sous corticale). Rev Neurol (Paris), 1985; 141: 706–712
Lanska DJ, Lanska MJ, Whitehouse PJ, Gambetti P. Familial progressive subcortical gliosis. Neurology, 1989; 39 (Suppl 1): 252
Lanska DJ, Currier RD, Cohen M, Gambetti P, Smith EE, Bebin J, Jackson JF, Whitehouse PJ, Markesberry WR. Familial progressive subcortical gliosis. Neurology, 1994; 44: 1633–1643
Lanska DJ, Markesbery WR, Cochran E, Bennett D, Lanska MJ, Cohen M. Late-onset sporadic progressive subcortical gliosis. J Neurol Sci, 1998; 157: 143–147
Mann DM. Dementia of frontal type and dementia with subcortical gliosis. Brain Pathol, 1998; 8: 325–338
Moosey J, Martinez J, Hanin I, Rao G, Yonas H, Boller F. Thalamic and subcortical gliosis with dementia. Arch Neurol, 1987: 44; 510–513
Neumann MA, Cohn R. Progressive subcortical gliosis, a rare form of pre-senile dementia. Brain, 1967; 90: 405–427
Petersen RB, Tabaton M, Chen SG, et al. Familial progressive subcortical gliosis: presence of prions and linkage to chromosome 17. Neurology, 1995; 45: 1062–1067
Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol, 1998; 43: 815–825
Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol, 1998; 8: 387–402
Tabaton M, Peterson RB, Monari L, et al. Progressive subcortical gliosis: a new prion protein disease. Soc Neurosci Abstr, 1993; 19: 842–844
Torack RM, Morris JC. Mesolimbocortical dementia: a clinicopathologic case study of a putative disorder. Arch Neurol, 1986;43: 1074–1078
Verity A, Wechsler AF. Progressive subcortical gliosis of Neumann: a clinicopathologic study of two cases with review. Arch Gerontol Geriatr, 1987; 6: 245–261
Will RG, Lees AJ, Barnard RO. A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome. J Neurol Neurosurg Psychiatry, 1988;51: 1224–1227
Balm MM, Paiche P. Abnormal diffusion weighted magnetic resonance images in Creutzfeldt-Jakob disease. Arch Neurol, 1999;56:577–583
Bruher H, Weber T, Thorwith V, Frahm J. In vivo monitoring of neuronal loss in Creutzfeld-Jakob disease by proton magnetic resonance spectroscopy. Lancet 1991; 337:1610–1611
Carrilho PM, Caramelli P, Albrecht S, Zatz M, LeBlanc A. Familial spongiform encephalopathy associated with a novel prion protein gene mutation. Ann Neurol, 1997; 42:138–146
Chesebro B. BSE and prions: uncertainties about the agent. Science, 1998;279:42–43
Demaerel P, Heiner L, Robberecht W, Sciot R, Wilms G. Diffusion weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology, 1999; 52: 205–208
Esiri MM, Gordon WI, Coolinge J, Patten JS. Peripheral neuropathy in Creutzfeldt-Jakob disease. Neurology, 1997; 48:784
Finkestaedt M, Szudra A, Zerr I, Poser S, Hise JH, Stoebner JM, Weber T. MR imaging of Creutzfeldt-Jakob disease. Radiology, 1996; 199:793–798
Gabizon R, Telliong G, Meiner Z, Halimi M, Kahana I, Prusiner SB. Insoluble wild-type and protease resistant mutant prion protein in brains of patients with inherited prion disease. Nature Med, 1996; 2: 59–64
Gajdusek DC, Zigas V. Degenerative diseases of the central nervous system in New Guinea: the endemic occurrence of kuru in the native population. N Engl J Med, 1957; 257:974–978
Gibbs CJ, Gajdusek DC, Asher DM, Alpers MP, Beck E, Daniel PM, Matthews WB. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science, 1968; 161:388–389
Gold M, Rojiani A, Murtaugh R. A 66-year-old woman with a rapidly progressing dementia and basal ganglia involvement. J Neuroimaging, 1997; 7: 171–175
Graham GD, Petroff OA, Blamire AM, Raikowska G, Goldman-Rakic P, Prichard JW. Proton magnetic resonance spectroscopy in Creutzfeldt-Jakob disease. Neurology, 1993;43:2065–2068
Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med, 1997;337: 1821–1828
Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet, 1997;349:99–100
Hitroshi S, Nagura H, Yamanouchi H, Kitamoto T. Double mutations at codon 180 and codon 232 of the PRNP gene in an apparently sporadic case of Creutzfeldt-Jakob disease. J Neurol Sci, 1993; 120: 208–211
Hsich G, Kenney K. Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med, 1996;335:923–930
Jakob A. Üher eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischen Befunde (spastische Pseudosclerose-encephalomyelopathie mit disseminierten Degenerationsherde). Dtsch Z Nervenheilkd, 1921; 70: 132–146
Johnson RT, Gibbs CJ. Creutzfeldt-Jakob disease and related spongiform encephalopathies. N Engl J Med, 1998; 339:1994–2004
Klatzo I, Gajdusek DC, Zigas V. Pathology of kuru. Lab Invest, 1959; 8: 799–847
Na DL, Suh CK, Choi SH, Moon HS, Seo DW, Kim SE, Na DG, Adair JC. Diffusion weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomical correlation. Arch Neurol, 1999; 56: 951–957
Nitrini R, Rosenberg S, Passos-Buena MR, Teixeira da Silva LS, Inghetti P, Papadopoulos M, Carrilho PM, Caramelli P, Albrecht S, Zatz M, LeBlanc A. Familial spongiform encephalopathy associated with a novel prion protein gene mutation. Ann Neurol, 1997; 42: 138–146
Priester JA de, Jansen GH, De Kruijk JR, Wilmink JT. New MRI findings in Creutzfeldt-Jakob disease: high signal in the globus pallidus on T1-weighted images. Neuroradiology, 1999;41:265–268
Prusiner SB, Scott M. Genetics of prions. Annu Rev Genet, 1997; 31: 139–175
Prusiner SB. Prion diseases and the BSE crisis. Science, 1997;278:245–251
Reder AT, Mednick AS, Brown, et al. Clinical and genetic studies of fatal familial insomnia. Neurology, 1995; 45:1968–1075
Sauman I, Schulz-Schaeffer WJ, Wohrle JC, Soumer A, Kretschmar MA, Hennerici M. Clinical range and MRI in Creutzfeldt-Jakob disease with heterozygosity at codon 129 and prion protein type 2. J Neurol Neurosurg Psychiatry, 1999; 67: 678–681
Urbach H. Creutzfeld-Jakob disease: analysis of the MR signal. Neuroreport 2000; 11: 5–6
Urbach H, Klisch J, Woilf HK, Brechtelsbauer D, Gass S, Solymosi C. MRI in sporadic Creutzfeldt-Jakob disease: correlation with clinical and neuropathological; data. Neuroradiology, 1998; 40: 65–70
Vrancken AF, Frijns CJM, Ramos LM. FLAIR MRI in sporadic Creutzfeldt-Jakob disease. Neurology, 2000; 55: 147–148
Wells GAH, Wilesmith JW. The neuropathology and epidemiology of bovine spongiform encephalopathy. Brain Pathol, 1995; 5: 91–103
Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeirok K, Alperovitch A, Poser S, Pocchiarti M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, 1996; 347: 921–925
Yoon SS, Chan S, Lee K, Goodman RR. MRI of Creutzfeldt-Jakob disease: asymmetric high signal intensity in the basal ganglia. Neurology, 1995; 45: 1932–1933
Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Birn DJ, Colchester AC, Durward W, Fletcher NA, Hawkins SA, Mackenzie JM, Will RG. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet, 1997; 350: 903–907
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Valk, J., Barkhof, F., Scheltens, P. (2002). Neurodegenerative Disorders. In: Magnetic Resonance in Dementia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56269-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-56269-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62597-8
Online ISBN: 978-3-642-56269-3
eBook Packages: Springer Book Archive